Efficacy and safety of antiplatelet drugs in the treatment of sepsis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050648

Enrollment

Unknown

Registered

2021-09-01

Start date

2021-11-15

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

experimental group:Aspirin + conventional treatment

control group:conventional treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Meet the diagnostic criteria for sepsis; 3. Not taking antiplatelet drugs 6 months before admission; 4. No serious malignant tumor, blood system disease or serious abnormal liver and kidney function; 5. Platelet count >= 50x10^9.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. There is a history of drug allergy in the past.

Design outcomes

Primary

Measure	Time frame
procalcitonin;White blood cell count;case fatality rate;acute physiology and chronic healthevaluation, APACHE?;sepsis related organfailure assessment, SOFA;	—

Countries

China

Contacts

Public ContactDeng Ximing

Graduate School of Bengbu Medical College

2645253977@qq.com+86 18895682618

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026